Now Enrolling Patients Diagnosed with Atrial Fibrillation “A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor Xla Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation